A5014516945- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- Advanced Radiotherapy Techniques
- Glioma Diagnosis and Treatment
- Advanced X-ray and CT Imaging
- Radiation Therapy and Dosimetry
- Hepatocellular Carcinoma Treatment and Prognosis
- Mass Spectrometry Techniques and Applications
- Neuroendocrine Tumor Research Advances
- Cardiac Imaging and Diagnostics
- Advanced MRI Techniques and Applications
- MRI in cancer diagnosis
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Chemical Reactions and Isotopes
- Brain Metastases and Treatment
- CAR-T cell therapy research
- Cell Adhesion Molecules Research
- Mathematical Biology Tumor Growth
- Cancer Immunotherapy and Biomarkers
- Orthopedic Infections and Treatments
- Lanthanide and Transition Metal Complexes
Klinikum rechts der Isar
2023-2025
Technical University of Munich
2023-2025
Parents' Place of Maryland
2025
Klinik und Poliklinik für Nuklearmedizin
2019-2025
Society of Nuclear Medicine and Molecular Imaging
2025
Ludwig-Maximilians-Universität München
2015-2024
LMU Klinikum
2018-2024
München Klinik
2019-2023
Radiopharmaceutical therapies (RPTs) with <sup>177</sup>Lu-prostate-specific membrane antigen (PSMA) ligands have demonstrated promising results for the treatment of metastatic castration-resistant prostate cancer. The lack absorbed-dose–effect relationships currently prevents patient-specific activity personalization. To ease implementation dosimetry in routine clinical workflow RPT, simplified methods such as single-time-point (STP) instead multiple-time-point (MTP) imaging protocols are...
β-emitting <sup>177</sup>Lu targeting prostate-specific membrane antigen (PSMA) is an approved treatment option for metastatic castration-resistant prostate cancer. Data on its long-term nephrotoxicity are sparse. This study aimed to retrospectively evaluate post–<sup>177</sup>Lu-PSMA estimated glomerular filtration rate (eGFR) dynamics at least 12 mo in a cohort of cancer patients. <b>Methods:</b> The institutional databases 3 German tertiary referral centers identified 106 patients who...
Because of challenges in performing routine personalized dosimetry radiopharmaceutical therapies, interest single-time-point (STP) dosimetry, particularly using only a single SPECT scan, is on the rise. Meanwhile, there are questions about reliability STP with limited independent validations. In present work, we analyzed 2 methods and evaluated dose errors for several radiopharmaceuticals based effective half-life distributions. <b>Methods:</b> We first challenged common assumption that...
Dosimetry for personalized radiopharmaceutical therapy has gained considerable attention. Many methods, tools, and workflows have been developed to estimate absorbed dose (AD). However, standardization is still required reduce variability of AD estimates across centers. One effort the Society Nuclear Medicine Molecular Imaging <sup>177</sup>Lu Challenge, which comprised 5 tasks (T1–T5) designed assess associated with imaging protocol (T1 vs. T2 T3), segmentation T4), time integration (T4...
Image-based dosimetry-guided radiopharmaceutical therapy has the potential to personalize treatment by limiting toxicity organs at risk and maximizing therapeutic effect. The <sup>177</sup>Lu dosimetry challenge of Society Nuclear Medicine Molecular Imaging consisted 5 tasks assessing variability in workflow. fifth task investigated associated with last step, dose conversion, workflow on which this study is based. <b>Methods:</b> Reference was assessed 2 medical physicists using different...
Computational nuclear oncology for precision radiopharmaceutical therapy (RPT) is a new frontier theranostic treatment personalization. A key strategy relies on the possibility to incorporate clinical, biomarker, image-based, and dosimetric information in digital twins (TDTs) of patients move beyond one-size-fits-all approach. The TDT framework enables optimization by real-time monitoring real-world system, simulation different scenarios, prediction resulting outcomes, as well facilitating...
Radiopharmaceutical therapy (RPT), with its targeted delivery of cytotoxic ionizing radiation, demonstrates significant potential for treating a wide spectrum malignancies, particularly unique benefits metastatic disease. There is an opportunity to optimize RPTs and enhance the precision theranostics by moving beyond one-size-fits-all approach using patient-specific image-based dosimetry personalized treatment planning. Such approach, however, requires accurate methods tools mathematic...
Individualized radiopharmaceutical therapies guided by patient-specific absorbed dose (AD) assessments using nuclear medicine imaging have the potential to improve both efficacy and safety. Understanding sources of variability in AD calculations is critical for standardization. The Society Nuclear Medicine Molecular Imaging Dosimetry Task Force launched 177Lu Challenge evaluate across steps within dosimetry workflow. This work aimed assess ADs due different fitting integration methods....
Ziel/Aim: Die Europäische Arzneimittel-Agentur (EMA) hat die [177Lu]Lu-PSMA-617 Radioligandentherapie (RLT) für Patienten mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC) einem festen Dosierungsschema von maximal 6 Zyklen à 7,4 GBq alle Wochen zugelassen. Jedoch könnte ein flexibleres und verlängertes Wirksamkeit der Behandlung erhöhen.
Single-time-point (STP) image-based dosimetry offers a more convenient approach for clinical practice in radiopharmaceutical therapy (RPT) compared with conventional multiple-time-point dosimetry. Despite numerous advancements, current STP methods are limited by the need strict and late timing data acquisition, posing challenges routine settings. This study introduces new concept of instant (iSTP) dosimetry, achieved predicting effective half-life (T eff) organs using machine learning...
Kratochwil C, et al. Targeted alpha therapy of mCRPC with 225actinium-PSMA-617: dosimetry estimate and empirical dose finding. J Nucl Med. 2017;8(10):1624–31 p. jnumed. 117.191395. Article Google Scholar Robertson A, Multi-isotope SPECT imaging the 225Ac decay chain: feasibility studies. Phys Med Biol. 2017;62(11):4406. CAS Usmani S, prostate-specific membrane antigen posttherapy α imaging: comparing 2 3 photopeaks. Clin 2019;44(5):401–3. Vatsa R, 225Ac-PSMA-617 radioligand in metastatic...
This work emphasizes that patient data, including images, are not operable (clinically), but digital twins are. Based on the former, latter can be created. Subsequently, virtual clinical operations performed towards selection of optimal therapies. Digital beginning to emerge in field medicine. We suggest theranostic (TDTs) amongst most natural and feasible flavors digitals twins. elaborate importance TDTs a future where 'one-size-fits-all' therapeutic schemes, as prevalent nowadays,...
The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM dosimetry relies on S values, which are pre-computed for reference anatomies, simplified activity distributions, and physiological distribution. However, mCRPC patients may show considerable lesion load, leads to heterogeneous patient-specific accumulation close BM-bearing sites. Furthermore, the distribution might be significantly...
Large datasets are required to ensure reliable non-invasive glioma assessment with radiomics-based machine learning methods. This can often only be achieved by pooling images from different centers. Moreover, trained models should perform high accuracy when applied data In this study, the impact of reconstruction settings and segmentation methods on radiomic features derived amino acid TSPO PET patients was examined. Additionally, ability model thus reduce feature differences...
Abstract Purpose 68 Ga-Trivehexin is an investigational PET radiopharmaceutical (NCT05799274) targeting αvβ6-integrin for imaging of carcinomas. 177 Lu-D0301 a structurally related therapeutic peptide tetramer. However, it showed considerable kidney uptake in rodents, impeding clinical applicability. We therefore evaluated the impact different protection strategies on biodistribution both agents normal and tumor-bearing mice. Methods Ex-vivo (90 min p.i.) 24 h was determined healthy C57BL/6N...
The bone marrow (BM) is a main organ at risk in Lu-177-PSMA-617 therapy of prostate cancer and Lu-177-Octreotate neuroendocrine tumours. BM dosimetry challenging time-consuming, as different sequential quantitative measurements must be combined. absorbed dose from the remainder body (ROB) can determined whole-body planar (WB-P) imaging, while Lu-177-SPECT allows for more robust tumour doses. aim was to investigate time-efficient patient-friendly hybrid protocol (HP) ROB BM. It combines three...
Abstract Background Patients with metastatic, castration-resistant prostate cancer (mCRPC) present an increased tumor burden in the skeleton. For these patients, Lutetium-177 (Lu-177) radioligand therapy targeting prostate-specific membrane antigen (PSMA) has gained increasing interest promising outcome data. Patient-individualized dosimetry enables improvement of success aim minimizing absorbed dose to organs at risk while maximizing tumors. Different dosimetric approaches varying...